Elekta
Elekta AB, commonly known as Elekta, is a leading innovator in the field of medical technology, headquartered in Stockholm, Sweden (SE). Founded in 1972, the company has established itself as a key player in the oncology and neurosurgery sectors, providing advanced solutions for cancer treatment and brain disorders. Elekta's core offerings include state-of-the-art radiation therapy systems, software solutions for treatment planning, and comprehensive patient management tools. What sets Elekta apart is its commitment to precision and personalised care, utilising cutting-edge technology to enhance treatment outcomes. With a strong presence in Europe, North America, and Asia, Elekta has achieved significant milestones, including numerous awards for innovation and excellence in healthcare. The company continues to lead the market, driven by its mission to improve the lives of patients worldwide through advanced medical solutions.
DitchCarbon Score
How does Elekta's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Elekta's score of 77 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Elekta's reported carbon emissions
In 2024, Elekta reported total greenhouse gas emissions of approximately 541,542,000 kg CO2e, with emissions distributed across various scopes: 6,141,000 kg CO2e (Scope 1), 3,760,000 kg CO2e (Scope 2), and a significant 531,640,000 kg CO2e (Scope 3). The Scope 3 emissions include categories such as business travel (17,071,000 kg CO2e) and the use of sold products (261,244,000 kg CO2e). Elekta has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 46.2% by FY2031, using FY2021 as the baseline. Additionally, the company plans to increase its annual sourcing of renewable electricity from 61% in FY2021 to 100% by FY2030. For Scope 3 emissions, Elekta targets a 55% reduction per radiotherapy cancer treatment course by FY2031, also from a FY2021 baseline. Furthermore, the company aims for 45% of its suppliers, based on emissions, to have science-based targets by FY2026. These commitments are aligned with the Science Based Targets initiative (SBTi) and reflect Elekta's dedication to addressing climate change within the healthcare equipment and supplies sector. The data reported is not cascaded from any parent organization, ensuring that these figures and targets are specific to Elekta AB (publ), headquartered in Sweden.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 1,576,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 444,082,520 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Elekta is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
